Charles River Laboratories Intl. Inc vs Hilton Hotels Corporation Common Stock — how do they compare? Charles River Laboratories Intl. Inc trades at $285.75 (market cap $13.46B), while Hilton Hotels Corporation Common Stock trades at $322.38 (market cap $70.82B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 5.3× Charles River Laboratories Intl. Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | HLT | |
|---|---|---|
Market Cap | $13.46B | $70.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $282.00 | $350.22 |
52-Week Low | $145.57 | $256.75 |
Enterprise Value | $16.30B | $83.83B |
Dividend Yield | — | 0.19% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Hilton Worldwide Holdings (HLT) trades at $322.51, up 3.7% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains solid fundamentals with revenue growth to $12.04B in 2025 and net income of $1.46B. Recent news highlights labor strikes and executive stock sales, while analyst consensus remains bullish with a $352 price target.
HLT offers growth potential from travel recovery and pipeline expansion, but faces risks from premium valuation (P/E 46.21), rising debt levels, and operational challenges. The stock trades near resistance at $316-$319, requiring strong Q3 earnings to sustain momentum amid mixed technical indicators.
Trailing returns across standard periods
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →